{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T11:56:54Z","timestamp":1764935814504,"version":"3.41.2"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.pharep.2016.01.002","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T17:49:58Z","timestamp":1453225798000},"page":"555-560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Propafenone enhances the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock model"],"prefix":"10.1007","volume":"68","author":[{"given":"Monika","family":"Banach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Piskorska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga K.","family":"Borowicz-Reutt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"5","key":"10.1016\/j.pharep.2016.01.002_bib0150","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1472-8206.1994.tb00817.x","article-title":"Classification and mechanism of action of antiarrhythmic drugs","volume":"8","author":"Scholz","year":"1994","journal-title":"Fundam Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.pharep.2016.01.002_bib0155","first-page":"1489","article-title":"Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone","volume":"34","author":"von Philipsborn","year":"1984","journal-title":"Arzneimittelforschung"},{"issue":"2","key":"10.1016\/j.pharep.2016.01.002_bib0160","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jemermed.2009.10.030","article-title":"Overdose of propafenone surreptitiously sold as Percocet","volume":"41","author":"D\u2019Orazio","year":"2011","journal-title":"J Emerg Med"},{"issue":"4","key":"10.1016\/j.pharep.2016.01.002_bib0165","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.pharep.2014.03.009","article-title":"Antiarrhythmic drugs and epilepsy","volume":"66","author":"Borowicz","year":"2014","journal-title":"Pharmacol Rep"},{"issue":"3","key":"10.1016\/j.pharep.2016.01.002_bib0170","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1212\/WNL.0b013e31827dec42","article-title":"HCN channels: function and clinical implications","volume":"80","author":"Benarroch","year":"2013","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.pharep.2016.01.002_bib0175","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1161\/CIRCULATIONAHA.112.000145","article-title":"New therapeutic targets in cardiology, heart failure and arrhythmia: HCN channels","volume":"127","author":"Roubille","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pharep.2016.01.002_bib0180","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1124\/mol.110.064683","article-title":"Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore","volume":"78","author":"Lipkind","year":"2010","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1016\/j.pharep.2016.01.002_bib0185","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(10)70059-4","article-title":"Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders","volume":"9","author":"Mantegazza","year":"2010","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.pharep.2016.01.002_bib0190","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.mp.4001087","article-title":"Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity","volume":"7","author":"Farber","year":"2002","journal-title":"Mol Psychiatry"},{"issue":"3","key":"10.1016\/j.pharep.2016.01.002_bib0195","first-page":"173","article-title":"Epilepsy and the heart","volume":"153","author":"Jallon","year":"1997","journal-title":"Rev Neurol (Paris)"},{"issue":"2","key":"10.1016\/j.pharep.2016.01.002_bib0200","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1358\/mf.2009.31.2.1338414","article-title":"The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drug","volume":"31","author":"Castel-Branco","year":"2009","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.pharep.2016.01.002_bib0205","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00213-007-0878-9","article-title":"Acute and chronic treatment with mianserin differentially affects the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model","volume":"195","author":"Borowicz","year":"2007","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pharep.2016.01.002_bib0210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","article-title":"A simplified method of evaluating dose-effect experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2016.01.002_bib0215","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000134913","article-title":"Une nouvelle methode simple pour explorer l\u2019action tranquilisante: le test de la cheminee","volume":"3","author":"Boissier","year":"1960","journal-title":"Med Exp (Basel)"},{"key":"10.1016\/j.pharep.2016.01.002_bib0220","first-page":"CD005049","article-title":"Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation","volume":"3","author":"Lafuente-Lafuente","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.pharep.2016.01.002_bib0225","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/oxfordjournals.eurheartj.a060852","article-title":"Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group","volume":"16","author":"Chimienti","year":"1995","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.pharep.2016.01.002_bib0230","doi-asserted-by":"crossref","first-page":"E223","DOI":"10.1532\/HSF98.20091173","article-title":"Efficacy of propafenone hydrochloride in preventing postoperative atrial fibrillation after coronary artery bypass grafting","volume":"13","author":"Ito","year":"2010","journal-title":"Heart Surg Forum"},{"issue":"5","key":"10.1016\/j.pharep.2016.01.002_bib0235","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.amjcard.2004.05.038","article-title":"Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting","volume":"94","author":"Kowey","year":"2004","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.pharep.2016.01.002_bib0240","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0002-9149(02)02867-9","article-title":"ERAFT Investigators. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol\/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study)","volume":"90","author":"Meinertz","year":"2002","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.pharep.2016.01.002_bib0245","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/hrt.67.6.491","article-title":"Short-term and long-term treatment with propafenone: determinants determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients with symptoms","volume":"67","author":"Zehender","year":"1992","journal-title":"Br Heart J"},{"issue":"1","key":"10.1016\/j.pharep.2016.01.002_bib0250","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ahj.2007.08.033","volume":"155","author":"Gulizia","year":"2008","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.pharep.2016.01.002_bib0255","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF03189870","article-title":"Tissue distribution of propafenone in the rat after intravenous administration","volume":"16","author":"Fern\u00e1ndez","year":"1991","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.pharep.2016.01.002_bib0260","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0002-8703(87)90735-6","article-title":"Distribution of propafenone and its active metabolite, 5-hydroxypropafenone, in human tissues","volume":"113","author":"Latini","year":"1987","journal-title":"Am Heart J"},{"issue":"Suppl 2","key":"10.1016\/j.pharep.2016.01.002_bib0265","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/j.1528-1157.1995.tb05996.x","article-title":"Antiepileptic drug mechanisms of action","volume":"36","author":"Macdonald","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharep.2016.01.002_bib0270","doi-asserted-by":"crossref","first-page":"D237","DOI":"10.1093\/nar\/gkp970","article-title":"SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions","volume":"38","author":"Preissner","year":"2010","journal-title":"Nucleic Acids Res"},{"issue":"27","key":"10.1016\/j.pharep.2016.01.002_bib0275","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.2174\/092986709789057635","article-title":"Substrates, inducers, inhibitors and structure- activity relationships of human Cytochrome P450 2C9 and implications in drug development","volume":"16","author":"Zhou","year":"2009","journal-title":"Curr Med Chem"},{"issue":"6","key":"10.1016\/j.pharep.2016.01.002_bib0280","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","article-title":"Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction","volume":"2","author":"Martignoni","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.pharep.2016.01.002_bib0285","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dos translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2007","journal-title":"FASEB J"},{"issue":"5","key":"10.1016\/j.pharep.2016.01.002_bib0290","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","article-title":"Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs","volume":"20","author":"L\u00f6scher","year":"2011","journal-title":"Seizure"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016000074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016000074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:36:23Z","timestamp":1752611783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2016.01.002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1734114016000074"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2016.01.002","relation":{},"ISSN":["1734-1140"],"issn-type":[{"type":"print","value":"1734-1140"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Propafenone enhances the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock model","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2016.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}